EBV status has prognostic implication among young patients with angioimmunoblastic T‐cell lymphoma
Abstract Epstein‐Barr virus (EBV)‐positive B cells have been detected in 66%‐86% of patients with angioimmunoblastic T‐cell lymphoma (AITL). However, it remains controversial whether EBV status has an impact on the survival of patients with AITL. In this study, we aimed to reevaluate the impact of E...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.2742 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849224371970768896 |
|---|---|
| author | Ahmed E. Eladl Kazuyuki Shimada Yuka Suzuki Taishi Takahara Seiichi Kato Kei Kohno Ahmed Ali Elsayed Chun‐Chieh Wu Takashi Tokunaga Tomohiro Kinoshita Mamiko Sakata‐Yanagimoto Shigeo Nakamura Akira Satou |
| author_facet | Ahmed E. Eladl Kazuyuki Shimada Yuka Suzuki Taishi Takahara Seiichi Kato Kei Kohno Ahmed Ali Elsayed Chun‐Chieh Wu Takashi Tokunaga Tomohiro Kinoshita Mamiko Sakata‐Yanagimoto Shigeo Nakamura Akira Satou |
| author_sort | Ahmed E. Eladl |
| collection | DOAJ |
| description | Abstract Epstein‐Barr virus (EBV)‐positive B cells have been detected in 66%‐86% of patients with angioimmunoblastic T‐cell lymphoma (AITL). However, it remains controversial whether EBV status has an impact on the survival of patients with AITL. In this study, we aimed to reevaluate the impact of EBV on the clinicopathological characteristics of AITL. In particular, we focused on the impact of EBV in younger patients with AITL. In total, 270 cases of AITL were studied. Epstein‐Barr virus‐positive B cells were detected in 191 (71%) cases (EBER+ group). Among the patients who received anthracycline‐based therapy, the EBER status did not affect the overall survival (OS) or progression‐free survival (PFS). In the younger group of AITL (≤60 years), PFS was significantly worse in the EBER− group compared to the EBER+ group (P = .0013). Furthermore, the multivariate analysis identified EBER‐negative status, thrombocytopenia, and elevated serum IgA level as significant adverse prognostic factors for PFS (P < .001, P < .001, and P = .002). Based on these findings, we constructed new prognostic model for the younger group, based on three adverse factors. We classified the patients into two risk groups: low risk (no or 1 adverse factor) and high risk (2 or 3 adverse factors). This new model for younger patients with AITL showed that both OS and PFS were significantly related to the level of risk (P < .0001). In summary, this study showed that, among younger patients with AITL, an EBER+ status significantly improved prognosis compared to an EBER− status. Our new prognostic model should be applicable to younger patients with AITL. |
| format | Article |
| id | doaj-art-7388bd846ec94de1b2e71bb229b1188e |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-7388bd846ec94de1b2e71bb229b1188e2025-08-25T10:14:05ZengWileyCancer Medicine2045-76342020-01-019267868810.1002/cam4.2742EBV status has prognostic implication among young patients with angioimmunoblastic T‐cell lymphomaAhmed E. Eladl0Kazuyuki Shimada1Yuka Suzuki2Taishi Takahara3Seiichi Kato4Kei Kohno5Ahmed Ali Elsayed6Chun‐Chieh Wu7Takashi Tokunaga8Tomohiro Kinoshita9Mamiko Sakata‐Yanagimoto10Shigeo Nakamura11Akira Satou12Department of Pathology and Laboratory Medicine Nagoya University Hospital Nagoya JapanDepartment of Hematology and Oncology Nagoya University Graduate School of Medicine Nagoya JapanDepartment of Pathology and Laboratory Medicine Nagoya University Hospital Nagoya JapanDepartment of Surgical Pathology Aichi Medical University Hospital Nagakute JapanDepartment of Pathology and Molecular Diagnostics Aichi Cancer Center Hospital Nagoya JapanDepartment of Pathology and Laboratory Medicine Nagoya University Hospital Nagoya JapanDepartment of Pathology and Laboratory Medicine Nagoya University Hospital Nagoya JapanDepartment of Pathology and Laboratory Medicine Nagoya University Hospital Nagoya JapanDepartment of Hematology and Oncology Research Nagoya Medical Center Nagoya JapanDepartment of hematology and Cell Therapy Aichi Cancer Center Nagoya JapanDepartment of Hematology Faculty of Medicine University of Tsukuba Tsukuba JapanDepartment of Pathology and Laboratory Medicine Nagoya University Hospital Nagoya JapanDepartment of Surgical Pathology Aichi Medical University Hospital Nagakute JapanAbstract Epstein‐Barr virus (EBV)‐positive B cells have been detected in 66%‐86% of patients with angioimmunoblastic T‐cell lymphoma (AITL). However, it remains controversial whether EBV status has an impact on the survival of patients with AITL. In this study, we aimed to reevaluate the impact of EBV on the clinicopathological characteristics of AITL. In particular, we focused on the impact of EBV in younger patients with AITL. In total, 270 cases of AITL were studied. Epstein‐Barr virus‐positive B cells were detected in 191 (71%) cases (EBER+ group). Among the patients who received anthracycline‐based therapy, the EBER status did not affect the overall survival (OS) or progression‐free survival (PFS). In the younger group of AITL (≤60 years), PFS was significantly worse in the EBER− group compared to the EBER+ group (P = .0013). Furthermore, the multivariate analysis identified EBER‐negative status, thrombocytopenia, and elevated serum IgA level as significant adverse prognostic factors for PFS (P < .001, P < .001, and P = .002). Based on these findings, we constructed new prognostic model for the younger group, based on three adverse factors. We classified the patients into two risk groups: low risk (no or 1 adverse factor) and high risk (2 or 3 adverse factors). This new model for younger patients with AITL showed that both OS and PFS were significantly related to the level of risk (P < .0001). In summary, this study showed that, among younger patients with AITL, an EBER+ status significantly improved prognosis compared to an EBER− status. Our new prognostic model should be applicable to younger patients with AITL.https://doi.org/10.1002/cam4.2742angioimmunoblastic T‐cell lymphomaEpstein‐Barr virusprognostic indicatorsurvival curveyoung |
| spellingShingle | Ahmed E. Eladl Kazuyuki Shimada Yuka Suzuki Taishi Takahara Seiichi Kato Kei Kohno Ahmed Ali Elsayed Chun‐Chieh Wu Takashi Tokunaga Tomohiro Kinoshita Mamiko Sakata‐Yanagimoto Shigeo Nakamura Akira Satou EBV status has prognostic implication among young patients with angioimmunoblastic T‐cell lymphoma Cancer Medicine angioimmunoblastic T‐cell lymphoma Epstein‐Barr virus prognostic indicator survival curve young |
| title | EBV status has prognostic implication among young patients with angioimmunoblastic T‐cell lymphoma |
| title_full | EBV status has prognostic implication among young patients with angioimmunoblastic T‐cell lymphoma |
| title_fullStr | EBV status has prognostic implication among young patients with angioimmunoblastic T‐cell lymphoma |
| title_full_unstemmed | EBV status has prognostic implication among young patients with angioimmunoblastic T‐cell lymphoma |
| title_short | EBV status has prognostic implication among young patients with angioimmunoblastic T‐cell lymphoma |
| title_sort | ebv status has prognostic implication among young patients with angioimmunoblastic t cell lymphoma |
| topic | angioimmunoblastic T‐cell lymphoma Epstein‐Barr virus prognostic indicator survival curve young |
| url | https://doi.org/10.1002/cam4.2742 |
| work_keys_str_mv | AT ahmedeeladl ebvstatushasprognosticimplicationamongyoungpatientswithangioimmunoblastictcelllymphoma AT kazuyukishimada ebvstatushasprognosticimplicationamongyoungpatientswithangioimmunoblastictcelllymphoma AT yukasuzuki ebvstatushasprognosticimplicationamongyoungpatientswithangioimmunoblastictcelllymphoma AT taishitakahara ebvstatushasprognosticimplicationamongyoungpatientswithangioimmunoblastictcelllymphoma AT seiichikato ebvstatushasprognosticimplicationamongyoungpatientswithangioimmunoblastictcelllymphoma AT keikohno ebvstatushasprognosticimplicationamongyoungpatientswithangioimmunoblastictcelllymphoma AT ahmedalielsayed ebvstatushasprognosticimplicationamongyoungpatientswithangioimmunoblastictcelllymphoma AT chunchiehwu ebvstatushasprognosticimplicationamongyoungpatientswithangioimmunoblastictcelllymphoma AT takashitokunaga ebvstatushasprognosticimplicationamongyoungpatientswithangioimmunoblastictcelllymphoma AT tomohirokinoshita ebvstatushasprognosticimplicationamongyoungpatientswithangioimmunoblastictcelllymphoma AT mamikosakatayanagimoto ebvstatushasprognosticimplicationamongyoungpatientswithangioimmunoblastictcelllymphoma AT shigeonakamura ebvstatushasprognosticimplicationamongyoungpatientswithangioimmunoblastictcelllymphoma AT akirasatou ebvstatushasprognosticimplicationamongyoungpatientswithangioimmunoblastictcelllymphoma |